← Back to Home

Survodutide meets cardiovascular safety threshold in Phase 3 trial, but heart-protective benefits remain unproven

The dual receptor agonist met its cardiovascular noninferiority endpoint, adding important evidence to its obesity development program; whether it can reduce cardiovascular events and whether patients can tolerate long-term treatment remain separate tests.

By SURL BioNews

Weight loss with a drug does not mean it has been proven to protect the heart. On November 9, results were announced from the Phase 3 SYNCHRONIZE-CVOT trial of survodutide, developed by Boehringer Ingelheim and licensed from Zealand Pharma, showing that it met the prespecified cardiovascular noninferiority endpoint. This supports its safety in populations at higher cardiovascular risk, but does not yet justify claims that it can prevent heart attacks or strokes.

According to information released by the two companies, the double-blind, placebo-controlled trial enrolled 5,530 adults with overweight or obesity who had cardiovascular disease, chronic kidney disease, or at least two weight-related complications or cardiovascular risk factors. Participants received once-weekly survodutide at 3.6 mg or 6.0 mg, or placebo. The results were presented at the American Heart Association Scientific Sessions and simultaneously published in The Lancet.

The primary endpoint included cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, and heart failure events. The hazard ratio for survodutide versus placebo was 0.89, with a 95% confidence interval of 0.67 to 1.18. For the three-component composite secondary endpoint of cardiovascular death, nonfatal myocardial infarction, and stroke, the hazard ratio was 0.84, with a 95% confidence interval of 0.60 to 1.18.

Both hazard ratios were below 1, but both confidence intervals crossed 1, so the figures cannot be directly interpreted as showing a significant reduction in cardiovascular events. A noninferiority trial tests whether risk remains within a prespecified acceptable margin; it does not establish that the risks in the two groups are exactly the same. In an interview with Pharmacy Times, principal investigator Biykem Bozkurt also noted that the trial was designed to demonstrate noninferiority and lacked sufficient statistical power to establish cardiovascular superiority.

Survodutide acts on both glucagon and GLP-1 receptors, seeking to combine appetite regulation with effects related to energy and liver metabolism. The companies also reported improvements in measures including blood pressure, waist circumference, and body weight. These changes help explain the drug’s metabolic effects, but cannot replace evidence on cardiovascular events themselves. The central significance of these results remains that the prespecified cardiovascular safety requirements were met.

Tolerability presents another challenge. In the 3.6 mg and 6.0 mg groups, respectively, 19.3% and 20.8% of participants discontinued treatment because of gastrointestinal adverse events, compared with 1.9% in the placebo group. Common symptoms included nausea, vomiting, diarrhea, and constipation, mostly mild to moderate. Pharmacy Times reported that most discontinuations occurred during dose escalation, when the original trial protocol allowed limited flexibility to slow escalation, adjust doses, or extend treatment interruptions. However, this explanation does not establish that a more flexible regimen would necessarily reduce discontinuation rates.

Zealand said Boehringer Ingelheim is advancing global marketing applications for obesity, while survodutide remains an investigational drug. For subsequent regulatory review and clinical development, this trial adds an important piece of cardiovascular safety evidence. Whether the drug offers additional heart-protective benefits, and whether more flexible dose escalation can improve treatment persistence, will each require their own evidence.

References

  1. Zealand Pharma
  2. Boehringer Ingelheim
  3. Pharmacy Times